MedTrace Logo

Low Dose Treosulfan Based Conditioning Regimen in HSCT for Nijmegen Breakage Syndrome

NCT04400045 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2020-06-25

No results posted yet for this study

Summary

The aim of the current study is to evaluate the safety and efficacy of low dose treosulfan based conditioning regimen in HSCT in Nijmegen breakage syndrome

Conditions

  • Nijmegen Breakage Syndrome

Interventions

DRUG

Treosulfan

Treosulfan 21mg/m2 (days -6, -5, -4)

Sponsors & Collaborators

  • Federal Research Institute of Pediatric Hematology, Oncology and Immunology

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
3 Months
Max Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-05-22
Primary Completion
2023-05-31
Completion
2023-05-31

Countries

  • Russia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04400045 on ClinicalTrials.gov